Abstract: In recent years, it has been found that the incidence of thrombophilia during pregnancy tends to increase. Thrombophilia is divided into inherited thrombophilia and acquired thrombophilia. Inherited thrombophilia is mainly related to abnormal protein expression caused by coagulation gene mutation, including factor V Leiden (FVL) mutation, prothrombin gene G20210A mutation, methylenetetrahydrofolate reductase (MTHFR) gene mutation, protein S (PS) deficiency, protein C (PC) deficiency and antithrombin (AT) deficiency. Coagulation, anticoagulation, and dysfunction of the fibrinolysis system can cause poor placental perfusion, and adverse pregnancy outcomes such as pre-eclampsia (PE), placental abruption, fetal growth restriction (FGR), and habitual abortion may be associated with this. However, whether inherited thrombophilia is a direct cause of adverse pregnancy outcomes and whether prophylactic anticoagulation can improve pregnancy outcomes remains to be further explored. This review aims to illustrate the relationship between inherited thrombophilia and adverse pregnancy outcomes, so as to assess the need for preventive anticoagulation, and to provide ideas for clinical diagnosis and treatment.

Key words: Thromboembolism, Thrombophilia, Pregnancy outcomes, Prothrombin, Anticoagulants, Therapy